25 May 2021 v2022.13.1 limited_company_frs_102_section_1a_v1_0_8 companies_houseSoftwarefalsetruetruetrueNo description of principal activity0xbrli:purexbrli:sharesiso4217:GBP134186062021-05-252021-12-31134186062021-12-3113418606bus:Director12021-05-252021-12-3113418606bus:Director12021-12-3113418606bus:Director22021-05-252021-12-3113418606bus:Director22021-12-3113418606bus:RegisteredOffice2021-05-252021-12-3113418606core:WithinOneYear2021-12-3113418606core:ShareCapital2021-12-3113418606core:RetainedEarningsAccumulatedLosses2021-12-3113418606core:RetainedEarningsAccumulatedLosses2021-05-252021-12-3113418606core:ShareCapital2021-05-252021-12-3113418606core:OfficeEquipment2021-05-252021-12-3113418606core:PlantMachinery2021-05-252021-12-3113418606core:PlantMachinery2021-12-311341860612021-05-252021-12-3113418606countries:EnglandWales2021-05-252021-12-3113418606bus:AuditExempt-NoAccountantsReport2021-05-252021-12-3113418606bus:PrivateLimitedCompanyLtd2021-05-252021-12-3113418606bus:SmallEntities2021-05-252021-12-3113418606bus:FullAccounts2021-05-252021-12-31
Company registration number:
13418606
Animo Healthcare Limited
Unaudited Financial Statements for the period ended
31 December 2021
Animo Healthcare Limited
Officers and Professional Advisers
Period ended
31 December 2021
Directors
J Chavoush
(appointed
25 May 2021
)
M Ishmail
(appointed
25 May 2021
)
Registered office
Ground Floor
13 Charles II Street
London
SW1Y 4QU
United Kingdom
Animo Healthcare Limited
Directors' Report
Period ended
31 December 2021
The directors present their report and the unaudited
financial statements
of the company for the period from 25 May 2021 to 31 December 2021.

Incorporation

The company was incorporated on
25 May 2021
as
Animo Healthcare Limited
.
The principal activity of the company is that of mental and behavioural healthcare consultants.

Directors

The directors who served the company during the period were as follows:
J Chavoush
(appointed
25 May 2021
)
M Ishmail
(appointed
25 May 2021
)

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.
This report was approved by the board of directors on
16 August 2022
and signed on behalf of the board by:
M Ishmail
Director
Animo Healthcare Limited
Income Statement
Period ended
31 December 2021
Period from 25 May 2021 to 31 Dec 2021
£
Turnover
31,667
 
Cost of sales
(34,975
)
Gross loss
(3,308
)
Administrative expenses
(47,440
)
Operating loss
(50,748
)
Loss before tax
(50,748
)
Tax on loss -  
Loss for the financial period
(50,748
)
The company has no other recognised items of income or expense other than the results for the period as set out above.
Animo Healthcare Limited
Statement of Financial Position
31 December 2021
31 Dec 2021
Note£
Fixed assets  
Tangible assets 5
1,349
 
Current assets  
Debtors 6
10,321
 
Cash at bank and in hand
27,263
 
37,584
 
Creditors: amounts falling due within one year 7
(89,581
)
Net current liabilities
(51,997
)
Total assets less current liabilities (50,648 )
Capital and reserves  
Called up share capital
100
 
Profit and loss account
(50,748
)
Shareholders deficit
(50,648
)
For the period ending
31 December 2021
, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
  • The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476;
  • The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These
financial statements
have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
These
financial statements
were approved by the board of directors and authorised for issue on
16 August 2022
, and are signed on behalf of the board by:
M Ishmail
Director
Company registration number:
13418606
Animo Healthcare Limited
Statement of Changes in Equity
Period ended
31 December 2021
Called up share capitalProfit and loss accountTotal
£££
At
25 May 2021
-   -   -  
Loss for the period -   (50,748 ) (50,748 )
Total comprehensive income for the period -  
(50,748
)
(50,748
)
Issue of shares
100
 - 
100
 
Total investments by and distributions to owners
100
 - 
100
 
At
31 December 2021
100
 
(50,748
)
(50,648
)
Animo Healthcare Limited
Notes to the Financial Statements
Period ended
31 December 2021

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is
Ground Floor
,
13 Charles II Street
,
London
,
SW1Y 4QU
, United Kingdom.

2 Statement of compliance

These
financial statements
have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

Basis of preparation

The
financial statements
have been prepared on the historical cost basis, as modified by the revaluation of certain assets.
The
financial statements
are prepared in sterling, which is the functional currency of the company.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for services supplied, net of discounts and Value Added Tax.
Revenue from the sale of services is recognised upon completion of the contractual obligations of the company.

Tangible assets

Tangible assets are initially measured at cost, and are subsequently measured at cost less any accumulated depreciation and accumulated impairment losses or at a revalued amount.
Any tangible assets carried at a revalued amount are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
An increase in the carrying amount of an asset as a result of a revaluation is recognised in other comprehensive income and accumulated in capital and reserves. However, the increase is recognised in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves. If a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess is recognised in profit or loss.
Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:
Office equipment
33% straight line

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.
Basic financial instruments are initially recognised at the transaction price and are subsequently measured as follows: Debt instruments are subsequently measured at amortised cost and commitments to receive a loan and to make a loan to another entity are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.
All other financial instruments, including derivatives, are initially recognised at fair value, which is normally the transaction price and are subsequently measured at fair value, with any changes recognised in profit or loss.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.
All equity instruments regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics.
Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4 Average number of employees

The average number of persons employed by the company during the period was Nil.

5 Tangible assets

Plant and machinery etc.
£
Cost  
At
25 May 2021
-  
Additions
1,388
 
At
31 December 2021
1,388
 
Depreciation  
At
25 May 2021
-  
Charge
39
 
At
31 December 2021
39
 
Carrying amount  
At
31 December 2021
1,349
 

6 Debtors

31 Dec 2021
£
Trade debtors
8,000
 
Amounts owed by group undertakings and undertakings in which the company has a participating interest
50
 
Other debtors
2,271
 
10,321
 

7 Creditors: amounts falling due within one year

31 Dec 2021
£
Trade creditors
57,543
 
Other creditors
32,038
 
89,581